Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia

QR Code

Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia

Antoni Sicras-Mainar,1 Jorge Maurino,2 Elena Ruiz-Beato,3 Ruth Navarro-Artieda4 1Badalona Serveis Assistencials SA, Badalona, Spain; 2Medical Department, Roche Farma SA, Madrid, Spain; 3Health Economics and Outcomes Research Unit, Roche Farma SA, Madrid, Spain; 4Department of Medical Information,...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Sicras-Mainar A, Maurino J, Ruiz-Beato E, Navarro-Artieda R
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2014
Sujets:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/80ed5fd8eed64ed1a4a123da9d80e436
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Use of antidepressants in the treatment of major depressive disorder in primary care during a period of economic crisis
par: Sicras-Mainar A, et autres
Publié: (2015)

Prevalence of metabolic syndrome and its association with depression in patients with schizophrenia
par: Suttajit S, et autres
Publié: (2013)

Pain perception in schizophrenia: influence of neuropeptides, cognitive disorders, and negative symptoms
par: Urban-Kowalczyk M, et autres
Publié: (2015)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
par: Ibrahim Turkoz, et autres
Publié: (2008)

Relationship between obesity and antipsychotic drug use in the adult population: A longitudinal, retrospective claim database study in Primary Care settings
par: Antoni Sicras-Mainar, et autres
Publié: (2008)

Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm
par: Cerveri G, et autres
Publié: (2019)

One patient with Sjogren’s syndrome presenting schizophrenia-like symptoms
par: Lin CE
Publié: (2016)

Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment
par: Correll CU, et autres
Publié: (2020)

Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study
par: Liang Y, et autres
Publié: (2017)

Prevalence of Metabolic Syndrome According to Causes of Physical Activity Limitation
par: Lee K, et autres
Publié: (2020)

Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
par: Boiko AS, et autres
Publié: (2020)

A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities
par: Liao X, et autres
Publié: (2021)

Update on the management of symptoms in schizophrenia: focus on amisulpride
par: Ann M Mortimer
Publié: (2009)

Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment
par: Iasevoli F, et autres
Publié: (2013)

Cognitive dysfunction and negative symptoms in patients with schizophrenia and their first-degree relatives from simplex and multiplex families
par: Zhang Z, et autres
Publié: (2018)

Measuring negative symptoms in patients with schizophrenia: reliability and validity of the Korean version of the Motivation and Pleasure Scale-Self-Report
par: Kim JS, et autres
Publié: (2016)

Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development
par: Gregory P. Strauss, et autres
Publié: (2021)

Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
par: Aleksandr M. Reznik, et autres
Publié: (2020)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study
par: Wani RA, et autres
Publié: (2015)

Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophrenia
par: Terzić T, et autres
Publié: (2015)

Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia
par: Mackle M, et autres
Publié: (2012)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum]
par: Wani RA, et autres
Publié: (2015)

Influence of CFH gene on symptom severity of schizophrenia
par: Zhang C, et autres
Publié: (2017)

Predictive Utility of Body Mass Index for Metabolic Syndrome Among Patients with Schizophrenia in Japan
par: Sugawara N, et autres
Publié: (2020)

Prevalence of bipolar spectrum disorder in Korean college students according to the K-MDQ
par: Bae SO, et autres
Publié: (2013)

An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
par: Giorgio L Colombo, et autres
Publié: (2008)

Psychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains?
par: Suttajit S, et autres
Publié: (2015)

Depressive symptoms and childhood sleep apnea syndrome
par: Carotenuto M, et autres
Publié: (2012)

Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
par: Fang X, et autres
Publié: (2019)

The prevalence and risk factors of stroke in patients with chronic schizophrenia
par: Liang Y, et autres
Publié: (2016)

Metacognitive Beliefs, Cognitive Functioning, Psychiatric Symptoms and Empathy in People with Schizophrenia
par: Chuang SP, et autres
Publié: (2021)

Validation of the Dutch Version of the Brief Negative Symptom Scale
par: Seelen-de Lang BL, et autres
Publié: (2020)

Prevalence and correlates of attention-deficit hyperactivity disorder symptoms in Korean college students
par: Kwak YS, et autres
Publié: (2015)

Validation of the Chinese Version of the 16-Item Negative Symptom Assessment
par: Huang B, et autres
Publié: (2020)

Neurological soft signs might be endophenotype candidates for patients with deficit syndrome schizophrenia
par: Albayarak Y, et autres
Publié: (2015)

Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial
par: Zhuo K, et autres
Publié: (2019)

Possible associations between antioxidant enzyme polymorphisms and metabolic abnormalities in patients with schizophrenia
par: Saruwatari J, et autres
Publié: (2013)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
par: Takada R, et autres
Publié: (2018)

Associations between stress and depression symptom profiles vary according to serotonin transporter polymorphism in rural Australians
par: Sharpley CF, et autres
Publié: (2018)

Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials
par: Michel Sabe, et autres
Publié: (2021)